What Earendil Labs does

Earendil Labs is a private, AI-driven biotechnology company founded in 2021 that designs and develops antibody and protein therapeutics for autoimmune, inflammatory, and oncology indications. Its core offering is an integrated biologics discovery platform that combines deep learning, generative protein engineering, structural biology, and high-throughput experimental validation in a closed design-build-test loop. The company positions itself as an AI-native biotech, not a tooling vendor: the same platform that produces candidates also generates the wet-lab data that retrain it.

The pipeline comprises 40+ disclosed biologics programs spanning multiple modalities — half-life-extended monoclonal antibodies (HXN-1001 anti-TL1A; HXN-1021 anti-OX40L), biparatopic antibodies (HXN-1011 anti-TSLP), bispecific antibodies (HX-16108 IL-13/IL-31), and T-cell engagers (HXN-1031 CD19/BCMA). Two programs are in the clinic as of mid-2026: HXN-1001 in Phase IIa for ulcerative colitis and HXN-1011 in Phase I for immunological disorders, with multiple IND submissions planned for 2026–2027. Manufacturing and ADC payloads are accessed via exclusive partnerships with WuXi Biologics (end-to-end bispecific/multispecific and ADC manufacturing) and WuXi XDC (exclusive global license to WuXiTecan-2 payload-linker technology).

Earendil is a B2B licensing biotech that monetizes its pipeline almost exclusively through strategic collaborations with large pharmaceutical companies, generating revenue through upfront payments, development and commercial milestones, and tiered royalties on net sales. Its flagship deal with Sanofi, signed in January 2026, is worth up to $2.56 billion for bispecific antibodies in autoimmune/inflammatory disease, supplementing an earlier ~$1.7 billion Sanofi autoimmune/inflammatory agreement. The company operates a multipolar footprint — Delaware incorporation, Beijing operational base affiliated with Helixon Therapeutics (华深智药), and Australian clinical sites — and raised $787 million in March 2026 to scale platform, pipeline, and headcount. It is reportedly considering a Hong Kong IPO.

Name

Earendil Labs

Legal name

Earendil Labs

Website

https://earendil.bio

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Earendil Labs is a private AI-driven biotechnology company that designs antibody and protein therapeutics for autoimmune, inflammatory, and oncology indications, licensing discovered candidates to large pharmaceutical partners (notably Sanofi) via upfront, milestone, and royalty agreements.

Ownership category

akta.pro rank

Product category

Biologics Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• AI drug discovery
• Biologics discovery
• Antibody engineering
• Protein therapeutics
• Antibody-drug conjugates

Headquarters

HQ city

Middletown

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Strategic Partnerships and Licensing: Earendil generates revenue through strategic collaborations with pharmaceutical companies including upfront payments, development and commercial milestone payments, and tiered royalties on net product sales. Notable deals include Sanofi's up to $2.56 billion collaboration.
2. Technology Licensing: Licensing of proprietary AI platforms and discovered molecules to pharmaceutical partners for development and commercialization

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Earendil Labs develops an AI-driven biologics discovery platform that combines deep learning, generative protein engineering, structural biology, and high-throughput experimental validation to discover and optimize novel antibody therapeutics. The company applies this platform to build a pipeline of more than 40 biologics programs across autoimmune, inflammatory, and oncology indications, which it out-licenses to large pharmaceutical partners for development and commercialization.

Product overview

Earendil Labs is an AI-driven biotechnology company developing a portfolio of antibody and biologics programs. The company's pipeline includes over 40 programs spanning multiple modalities: HXN-1001 (anti-TL1A antibody for IBD in Phase II), HXN-1011 (anti-TSLP biparatopic antibody in Phase I), HXN-1021 (anti-OX40L antibody), HX-16108 (bispecific IL-13/IL-31 antibody), and HXN-1031 (CD19/BCMA bispecific T-cell engager for B-cell malignancies). The AI platform integrates deep learning, generative protein engineering, structural biology, and high-throughput experimental validation for antibody discovery and optimization, with strategic manufacturing partnerships with WuXi Biologics and WuXi XDC leveraging WuXiTecan-2 ADC technology.

Differentiator

Problem solved

Functional benefit

Products and services

• HXN-1001 Half-life extended anti-TL1A antibody being developed for ulcerative colitis and inflammatory bowel disease, with Phase I data showing approximately 8-week half-life and a well-tolerated safety profile.
• HXN-1011 Biparatopic antibody targeting TSLP for immunological disorders including asthma, atopic dermatitis, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and COPD.
• HXN-1021 Anti-OX40L antibody with potent activity and extended half-life targeting the OX40L-OX40 T-cell costimulatory pathway implicated in multiple autoimmune diseases including atopic dermatitis.
• HX-16108 Bispecific antibody targeting both IL-13 and IL-31 cytokines for atopic dermatitis and inflammatory skin diseases with pruritus.
• HXN-1031 Bispecific T-cell engager targeting both CD19 and B-cell maturation protein (BCMA) for B-cell malignancies.

Quantifiable outcome

• 40+ biologics programs in pipeline
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• WuXi BiologicscoreStrategic or Co-development Partner · 12 March 2026Strategic collaboration for development and manufacturing of bispecific/multispecific antibodies and ADCs targeting autoimmune disease, cancer, and other diseases. WuXi Biologics provides end-to-end biologics development and manufacturing services including cell line development, process development, and GMP manufacturing.
• WuXi XDCcoreOEM/ Whitelabel/ Licensing Partner · 27 February 2026Exclusive global license to WuXiTecan-2 payload-linker technology platform for developing next-generation ADCs. Total potential deal value up to $885 million including upfront, milestone payments, and tiered royalties. WuXi XDC supports CMC development and manufacturing while Earendil leads product development and commercialization.
• SanoficoreStrategic or Co-development Partner · 5 January 2026Strategic collaboration to discover bispecific antibodies for autoimmune and inflammatory diseases. Sanofi leads development and worldwide commercialization. Deal includes up to $160 million upfront with total potential value reaching $2.56 billion plus tiered royalties on net product sales.
• SanoficoreStrategic or Co-development Partner · 1 January 2025Prior licensing agreements for autoimmune and inflammatory disease programs including a $1.7 billion licensing deal, establishing ongoing strategic relationship with Sanofi.

Scale indicators6 records

Recent moves6 records

Expansion highlights7 records

Emerging players

• BigHat Biosciences: AI-driven antibody engineering platform combining ML-guided design with high-throughput wet-lab validation. Smaller and earlier-stage than Earendil but highly comparable in core technology approach — generative protein engineering with tight computational-experimental iteration loops for antibody optimization.
• Antiverse: AI-based antibody discovery platform using generative models to design antibody candidates. Comparable as an emerging AI-antibody-design peer, though substantially smaller and earlier-stage than Earendil with no disclosed late-stage clinical assets.
• EvolutionaryScale (ESM): AI protein language model company developing foundation models for protein design, with applications in therapeutic discovery. Comparable as a frontier-AI-protein-design peer intersecting with Earendil's generative engineering focus, though primarily infrastructure-oriented rather than a pipeline developer.

Direct peers

• Insitro: AI-driven drug discovery company combining machine learning with high-throughput biology to discover and develop therapeutics. Comparable as a direct AI-biologics platform peer with pharma partnerships and venture-scale funding, though Insitro's pipeline is weighted toward small-molecule and metabolic disease rather than antibody discovery.
• Isomorphic Labs: Alphabet-backed AI drug discovery company applying DeepMind's protein-structure prediction to therapeutic discovery with pharma partnerships including Novartis and Eli Lilly. Comparable as a generative biology platform peer, though with substantially greater capital backing and broader partnership scope.
• Generate Biomedicines: Generative AI platform for protein therapeutics design with pharma partnerships including Amgen and Eli Lilly. Highly comparable — both companies use generative protein engineering to design novel antibodies and biologics for licensing to large pharma, and both emphasize platform productivity as a core metric.
• Adimab: Industry-leading antibody discovery and engineering platform that licenses antibody candidates to pharma partners. Comparable as a discovery-platform business model peer (licensing/royalty revenue, no direct commercialization), though Adimab emphasizes wet-lab technology and yeast-display rather than AI-driven design.
• AbCellera Biologics: Pure-play antibody discovery platform using high-throughput single-cell screening, AI, and engineering to discover therapeutic antibodies for pharma partners. Most directly comparable peer — both monetize via licensing to large pharma and operate technology platforms producing antibody candidates across multiple indications.
• Xaira Therapeutics: AI-first drug discovery company launched in 2024 with $1B Series A, applying generative AI to protein design and small-molecule discovery. Comparable as a recently-funded generative-AI-biologics peer with similar platform ambitions and pharma partnership strategy, though earlier in commercial validation.
• Recursion Pharmaceuticals: AI-enabled drug discovery company combining high-dimensional biology, chemistry, and ML to discover therapeutics across multiple modalities. Comparable as a publicly-traded AI-drug-discovery peer with a similar platform-licensing and pipeline-development business model, though Recursion's pipeline is more small-molecule weighted.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Earendil Labs